{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:17:38Z","timestamp":1793733458707,"version":"4.6.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016930","name":"Ferring Research Institute Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016930","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncolytics"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.omto.2021.11.006","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T22:56:56Z","timestamp":1636671416000},"page":"547-559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-5476","authenticated-orcid":false,"given":"Jennifer L.","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1146-9915","authenticated-orcid":false,"given":"Robin E.","family":"Osterhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7606-9862","authenticated-orcid":false,"given":"Amy L.","family":"Klova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8895-3495","authenticated-orcid":false,"given":"Carsten","family":"Merkwirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3127-7101","authenticated-orcid":false,"given":"Scott R.P.","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza Beheshti","family":"Zavareh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2149-3081","authenticated-orcid":false,"given":"Bryan C.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeela","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn S.","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2021.11.006_bib1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in\u00a0situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.omto.2021.11.006_bib2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur. Urol."},{"key":"10.1016\/j.omto.2021.11.006_bib3","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/sj.cgt.7700364","article-title":"Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers","volume":"8","author":"Iqbal Ahmed","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2021.11.006_bib4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.urology.2005.02.015","article-title":"Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens","volume":"66","author":"Connor","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.omto.2021.11.006_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2021.11.006_bib6","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFNalpha\/syn3 for patients with high-grade, Bacillus calmette-guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.11.006_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons alpha and beta in cancer: therapeutic opportunities from new insights","volume":"18","author":"Borden","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omto.2021.11.006_bib8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omto.2021.11.006_bib9","doi-asserted-by":"crossref","first-page":"71249","DOI":"10.18632\/oncotarget.19531","article-title":"Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy","volume":"8","author":"Medrano","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2021.11.006_bib10","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T\u00a0cell receptor (TCR) transgenic CD8+ T\u00a0cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2021.11.006_bib11","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3389\/fimmu.2019.01906","article-title":"CD8(+) T Lymphocyte and NK cell network: circuitry in the cytotoxic domain of immunity","volume":"10","author":"Uzhachenko","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.omto.2021.11.006_bib12","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1158\/0008-5472.CAN-04-1909","article-title":"Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells","volume":"64","author":"Papageorgiou","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2021.11.006_bib13","first-page":"265","article-title":"Antiproliferative effects of interferons against human bladder carcinoma cell lines in\u00a0vitro","volume":"43","author":"Grups","year":"1988","journal-title":"Urol. Int."},{"key":"10.1016\/j.omto.2021.11.006_bib14","first-page":"3252","article-title":"Independent sensitivity of human tumor cell lines to interferon and double-stranded RNA","volume":"44","author":"Hubbell","year":"1984","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2021.11.006_bib15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ymthe.2004.05.027","article-title":"Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein","volume":"10","author":"Benedict","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2021.11.006_bib16","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/cgt.2008.53","article-title":"Conditioned medium from Ad-IFN-alpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect","volume":"15","author":"Zhang","year":"2008","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2021.11.006_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.cgt.7701011","article-title":"Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects","volume":"14","author":"Zhang","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2021.11.006_bib18","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/bjc.1970.89","article-title":"A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosome pattern and ultrastructure","volume":"24","author":"Rigby","year":"1970","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omto.2021.11.006_bib19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0022-5347(17)45139-1","article-title":"Improved growth of human urothelial carcinoma cell cultures","volume":"136","author":"Grossman","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.omto.2021.11.006_bib20","first-page":"5810","article-title":"Morphological, biological, biochemical, and karyotypic characteristics of human pancreatic ductal adenocarcinoma Capan-2 in tissue culture and the nude mouse","volume":"46","author":"Kyriazis","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.omto.2021.11.006_bib21","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0022-5347(05)00323-X","article-title":"Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression","volume":"175","author":"Sabichi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.omto.2021.11.006_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/bjc.1977.21","article-title":"A cell line from an anaplastic transitional cell carcinoma of human urinary bladder","author":"Nayak","year":"1977","journal-title":"Br J Cancer"},{"key":"10.1016\/j.omto.2021.11.006_bib23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ijc.2910110327","article-title":"Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen","volume":"11","author":"Bubenik","year":"1973","journal-title":"Int J Cancer"},{"key":"10.1016\/j.omto.2021.11.006_bib24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/ijc.2910170604","article-title":"A cell line (SCABER) derived from squamous cell carcinoma of the human urinary bladder","volume":"17","author":"O\u2019Toole","year":"1976","journal-title":"Int J Cancer"},{"key":"10.1016\/j.omto.2021.11.006_bib25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jnci\/58.4.881","article-title":"Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses","volume":"58","author":"Rasheed","year":"1977","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.omto.2021.11.006_bib26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/bjc.1978.164","article-title":"Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma","volume":"38","author":"O\u2019Toole","year":"1978","journal-title":"Br J Cancer"},{"key":"10.1016\/j.omto.2021.11.006_bib27","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.omto.2021.11.006_bib28","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1007\/s00262-020-02609-5","article-title":"Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer","volume":"69","author":"Long","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omto.2021.11.006_bib29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1089\/jir.2010.0112","article-title":"The small interferon-induced transmembrane genes and proteins","volume":"31","author":"Siegrist","year":"2011","journal-title":"J.\u00a0Interferon Cytokine Res."},{"key":"10.1016\/j.omto.2021.11.006_bib30","doi-asserted-by":"crossref","first-page":"8971","DOI":"10.1038\/ncomms9971","article-title":"Systematic pan-cancer analysis of tumour purity","volume":"6","author":"Aran","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omto.2021.11.006_bib31","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omto.2021.11.006_bib32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41591-018-0302-5","article-title":"Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss","volume":"25","author":"Liu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2021.11.006_bib33","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","article-title":"IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T\u00a0cell-mediated immunity","volume":"186","author":"Terawaki","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omto.2021.11.006_bib34","doi-asserted-by":"crossref","first-page":"e1577125","DOI":"10.1080\/2162402X.2019.1577125","article-title":"Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation","volume":"8","author":"Plote","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.omto.2021.11.006_bib35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ccell.2020.11.006","article-title":"DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity","volume":"39","author":"Lu","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2021.11.006_bib36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00302471","article-title":"Interferon receptors on the surface of interferon-sensitive and interferon-resistant urothelial carcinomas","volume":"18","author":"Grups","year":"1990","journal-title":"Urol. Res."},{"key":"10.1016\/j.omto.2021.11.006_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/JLB.2MIR0817-342R","article-title":"Negative regulation of type I IFN signaling","author":"Arimoto","year":"2018","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.omto.2021.11.006_bib38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10555-009-9194-7","article-title":"Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer","volume":"28","author":"McConkey","year":"2009","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.omto.2021.11.006_bib39","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2021.11.006_bib40","doi-asserted-by":"crossref","first-page":"38531","DOI":"10.1038\/srep38531","article-title":"FOXA1, GATA3 and PPAR cooperate to drive luminal subtype in bladder cancer: a molecular analysis of established human cell lines","volume":"6","author":"Warrick","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omto.2021.11.006_bib41","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3389\/fimmu.2018.01135","article-title":"A positive feedback amplifier circuit that regulates interferon (IFN)-Stimulated gene expression and controls type I and type II IFN responses","volume":"9","author":"Michalska","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.omto.2021.11.006_bib42","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Stark","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.omto.2021.11.006_bib43","doi-asserted-by":"crossref","first-page":"eaah4248","DOI":"10.1126\/scisignal.aah4248","article-title":"Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections","volume":"10","author":"Wang","year":"2017","journal-title":"Sci. Signal"},{"key":"10.1016\/j.omto.2021.11.006_bib44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1468-1331.1998.520187.x","article-title":"Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration","volume":"5","author":"Munafo","year":"1998","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.omto.2021.11.006_bib45","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1089\/10799900050163226","article-title":"Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers","volume":"20","author":"Buchwalder","year":"2000","journal-title":"J.\u00a0Interferon Cytokine Res."},{"key":"10.1016\/j.omto.2021.11.006_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2210-10-15","article-title":"Pharmacokinetic and pharmacodynamic comparison of two \"pegylated\" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study","volume":"10","author":"Garcia-Garcia","year":"2010","journal-title":"BMC Pharmacol."},{"key":"10.1016\/j.omto.2021.11.006_bib47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2036.2007.03392.x","article-title":"Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naive patients with chronic hepatitis C: a randomized, controlled study","volume":"26","author":"Bruno","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.omto.2021.11.006_bib48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-0-12-800267-4.00003-1","article-title":"Recognition of tumors by the innate immune system and natural killer cells","volume":"122","author":"Marcus","year":"2014","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.omto.2021.11.006_bib49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the 'missing self': MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol. Today"},{"key":"10.1016\/j.omto.2021.11.006_bib50","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1006\/mthe.2001.0464","article-title":"Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models","volume":"4","author":"Qin","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2021.11.006_bib51","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/j.1349-7006.2010.01578.x","article-title":"Administration route-dependent induction of antitumor immunity by interferon-alpha gene transfer","volume":"101","author":"Narumi","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omto.2021.11.006_bib52","first-page":"83","article-title":"Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases","volume":"108","author":"Tada","year":"2001","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2021.11.006_bib53","first-page":"6201","article-title":"Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity","volume":"61","author":"Odaka","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2021.11.006_bib54","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1006\/mthe.2002.0656","article-title":"Analysis of the immunologic response generated by Ad.IFN-\u03b2 during successful intraperitoneal tumor gene therapy","volume":"6","author":"Odaka","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2021.11.006_bib55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00251-010-0494-4","article-title":"Frequent loss of heterozygosity in the beta2-microglobulin region of chromosome 15 in primary human tumors","volume":"63","author":"Maleno","year":"2011","journal-title":"Immunogenetics"},{"key":"10.1016\/j.omto.2021.11.006_bib56","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.it.2015.02.003","article-title":"The STING pathway and the T\u00a0cell-inflamed tumor microenvironment","volume":"36","author":"Woo","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.omto.2021.11.006_bib57","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omto.2021.11.006_bib58","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","article-title":"The nf-core framework for community-curated bioinformatics pipelines","volume":"38","author":"Ewels","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omto.2021.11.006_bib59","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1093\/nar\/gks042","article-title":"Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation","volume":"40","author":"McCarthy","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omto.2021.11.006_bib60","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omto.2021.11.006_bib61","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J.\u00a0Open Source Softw."},{"key":"10.1016\/j.omto.2021.11.006_bib62","series-title":"Package \u2018pheatmap\u2019. Available at: https:\/\/cran.r-project.org\/web\/packages\/pheatmap\/index.html. Accessed September 15, 2021","author":"Kolde","year":"2019"},{"key":"10.1016\/j.omto.2021.11.006_bib63","doi-asserted-by":"crossref","first-page":"180061","DOI":"10.1038\/sdata.2018.61","article-title":"Unifying cancer and normal RNA sequencing data from different sources","volume":"5","author":"Wang","year":"2018","journal-title":"Sci. Data"},{"key":"10.1016\/j.omto.2021.11.006_bib64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nbt.2203","article-title":"Absolute quantification of somatic DNA alterations in human cancer","volume":"30","author":"Carter","year":"2012","journal-title":"Nat. Biotechnol."}],"container-title":["Molecular Therapy Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770521001558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770521001558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:35:56Z","timestamp":1784723756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770521001558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":64,"alternative-id":["S2372770521001558"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2021.11.006","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2021.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}]}}